Clinical trials: Advanced Solid Tumors (Phase 1)
KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combination with other agents in…
- Trial name
- NCT07094113
- Testing
- AMG 410, Pembrolizumab, Panitumumab
- Where
- 39 sites in United States, Australia and 12 more
- Volunteers
- 434 people
- Sponsor
- Amgen
Advanced Solid Tumors
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study.
- Trial name
- NCT06959706
- Testing
- TGW101
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Tagworks Pharmaceuticals BV
Advanced Malignant Solid Tumours
Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.
This study aims to explore the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB14 as a monotherapy in adult patients with advanced malignant solid tumours.
- Trial name
- NCT06304818
- Testing
- SCTB14
- Volunteers
- 515 people
- Sponsor
- Sinocelltech Ltd.
Sarcoma, Castrate Resistant Prostate Cancer
A Study of PRT2527 in Participants With Advanced Solid Tumors
This is a Phase 1 dose-escalation and confirmation study of PRT2527, a Cyclin-dependent Kinase 9 (CDK9) inhibitor, in participants with advanced solid tumors.
- Conditions
- Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05159518
- Testing
- PRT2527
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Prelude Therapeutics Incorporated
HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors
A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SHR-4602 in subjects with HER2-expressing or HER2-mutated locally advanced or metastatic solid tumors.
- Trial name
- NCT06560138
- Testing
- SHR-4602
- Where
- 5 sites in Australia
- Sponsor
- Atridia Pty Ltd.
Advanced Solid Tumors
Study of CHO-A04 in Advanced Solid Tumors
The goal of this clinical trial is to learn if the study drug, CHO-A04, works to treat solid cancers in adults. It will also aim to learn about the safety of CHO-A04 and find the best dose to use in future cancer treatment.
- Trial name
- NCT07049458
- Testing
- CHO-A04
- Where
- Taiwan
- Volunteers
- 62 people
- Sponsor
- Cho Pharma Inc.
Neoplasm
Safety Study of Infusion of SGT-53 to Treat Solid Tumors
This is a Phase Ib study as a continuation of the original Phase I protocol. The purpose of this Phase Ib study is to evaluate the safety of a single course of SGT-53 in combination with docetaxel and determine the recommended…
- Trial name
- NCT00470613
- Testing
- SGT-53
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- SynerGene Therapeutics, Inc.
Neoplasms
AZD5438 in Patients With Advanced Solid Malignancies
Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to patients with advanced solid malignancies A review of the emerging clinical tolerability and exposure data from this study in conjunction…
- Trial name
- NCT00088790
- Testing
- AZD5438
- Where
- 2 sites in United States
- Sponsor
- AstraZeneca
Malignant Solid Tumors
Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
This is a phase I, multicenter, open-label dose escalation and expansion study to evaluate genakumab alone and in combination with tislelizumab in adult patients with advanced solid malignancies.
- Trial name
- NCT05441046
- Testing
- Genakumab
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Advanced Cancer
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
SGX523 is a drug which acts by blocking the function of an enzyme called MET. MET activity may be important in growth and survival of some types of cancer.
- Trial name
- NCT00606879
- Testing
- SGX523 Capsules
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- SGX Pharmaceuticals, Inc.
Advanced Solid Tumor
Study of LM-302 in Patients With Advance Solid Tumors
A Phase I/II Study of LM-302 in Patients with CLDN18.2-Positive Advanced Solid Tumors
- Trial name
- NCT05161390
- Testing
- LM-302 Injection
- Where
- China
- Volunteers
- 153 people
- Sponsor
- LaNova Medicines Zhejiang Co., Ltd.
Stage III Prostate Carcinoma, Stage IV Prostate Carcinoma
Dose Finding Safety Study of VAL201 in Cancer Patients
Dose finding safety study of VAL201 in cancer patients.
- Trial name
- VAL201-001 (NCT02280317)
- Testing
- VAL201
- Volunteers
- 12 people
- Sponsor
- ValiRx Plc
Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC)
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
This is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are…
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
- Trial name
- NCT06792435
- Testing
- XNW27011
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced or Metastatic Solid Tumors, Advanced or Metastatic Colorectal Cancer (mCRC)
First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Study HS-CA102N-101 is a phase 1, two part (dose escalation, dose expansion), multicenter, non-randomized, open-label, multiple dose, first-in-human study of CA102N monotherapy and of CA102N combined with trifluridine/tipiracil…
- Trial name
- NCT03616574
- Testing
- CA102N, LONSURF
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
Advanced Solid Tumor
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors
- Trial name
- NCT06260774
- Testing
- TTX-MC138
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- TransCode Therapeutics
Advanced Solid Tumor
Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients
This is an open-label study in advanced solid tumor patients to determine if entrectinib affects the pharmacokinetics of midazolam and any of its pharmacologically active metabolites.
- Trial name
- NCT03330990
- Testing
- Entrectinib, Midazolam Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors
The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor
This study will evaluate the safety, tolerability, pharmacokinetics, food effect, and preliminary antitumor activities of BGB-283 in Chinese subjects with local advanced or metastatic malignant solid tumor.
- Trial name
- NCT03641586
- Testing
- BGB-283
- Where
- China
- Volunteers
- 42 people
- Sponsor
- BeiGene
Advanced Solid Tumors
Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
Single arm, open label, Phase I, dose-escalation study of indibulin in combination with erlotinib in subjects with advanced histologically confirmed, solid tumors for which no standard therapy exists and for whom treatment with…
- Trial name
- NCT00591383
- Testing
- indibulin, erlotinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Alaunos Therapeutics
Advanced Cancer, Metastatic Cancer
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
This clinical trial is evaluating a drug called ART4215 in participants with advanced or metastatic solid tumors. The main goals of this study are to: Find the recommended dose of ART4215 that can be given safely to participants…
- Conditions
- Advanced Cancer, Metastatic Cancer, Breast Cancer
- Trial name
- NCT04991480
- Testing
- ART4215, Talazoparib, Niraparib
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 93 people
- Sponsor
- Artios Pharma Ltd
Advanced Solid Tumor
A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors
The primary objective is to determine the safety profile of SH3051 in subjects with advanced solid tumors. The second objective is to evaluate the PK profile and preliminary efficacy of SH3051 solid tumors.
- Trial name
- NCT04423380
- Testing
- SH3051 capsule treatment
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.